Table 5 Non-manifesting carriers’ Metabolic Syndrome components.

From: Metabolic syndrome does not influence the phenotype of LRRK2 and GBA related Parkinson’s disease

 

Control

LRRK2-NMC

GBA-NMC

Significance

#

196

55

97

 

HDL (mg/Dl)

56.45 (15.76)

56.44 (14.47)

57.84 (17.16)

0.694

Triglycerides (mg/Dl)

136.89 (75.66)

146.36 (105.63)@

142.00 (75.01)

0.014*

HbA1c (%)

5.49 (0.48)

5.45 (0.43)

5.44 (0.44)

0.683

BMI (kg/m2)

26.36 (4.78)

26.15 (4.26)

26.66 (4.69)

0.785

Hypo-HDL (%)

18.97%

23.63%

24.21%

0.525

Hypertriglyceridemia (%)

43.58%

56.36%

49.47%

0.619

Prediabetes (%)

30.25%

21.81%

25.26%

0.393

Hypertension (%)

65.12%

58.18%

58.90%

0.469

Obesity (BMI > 30) (%)

20.51%

14.54%

27.36%

0.163

  1. NMC- Non-Manifesting Carriers, HDL- High Density Lipoprotein, HbA1c – Hemoglobin A1C, BMI- Body Mass Index. *Significant after correcting for multiple comparisons with Bonferroni adjustment.
  2. @Differences between LRRK2-NMC and GBA-NMC, control.
Back to article page